Article
ERG induces taxane resistance in castration-resistant prostate cancer
25 Nov 2014
Abstract excerpt
Taxanes are the only chemotherapies used to treat patients with metastatic castration-resistant prostate cancer (CRPC). Despite the initial efficacy of taxanes in treating CRPC, all patients ultimately fail due to the development of drug resistance. In this study, we show that ERG overexpression in in vitro and in vivo models of CRPC is associated with decreased sensitivity to taxanes. ERG affects several...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
